Aditya Birla Sunlife Life Pharma & Healthcare IDCW Reinvest Direct Plan
SIP amount
Min. ₹100
Lumpsum amount
Min. ₹1,000

Aditya Birla Sunlife Life Pharma & Healthcare IDCW Reinvest Direct Plan

NAV
₹22.2300
+0.32%
(28 Mar)
AUM
755 Cr
TER
1.1%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is above its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+12.9%
+6.7%
+6.7%
+6.7%
+5.7%
3Y
+18.4%
+32.4%
+32.4%
+32.4%
+30.8%
5Y
+26.3%
+33.6%
+33.6%
+33.6%
+33.0%
ALL
+22.1%
+11.7%
+11.7%
+11.7%
+16.3%
VOL
17.1%
20.4%
20.4%
20.4%
20.2%
TER
1.1%
1.0%
1.0%
1.0%
0.9%
AUM
₹755 Cr
₹4,149 Cr
₹4,149 Cr
₹4,149 Cr
₹1,047 Cr
INFO
1.29
0.57
0.57
0.57
0.80
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
Aditya Birla Sunlife Life Pharma & Healthcare IDCW Reinvest (DR)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 28th Feb
Top holdings
Sun Pharmaceuticals Industries Ltd
14.5%
Cipla Ltd
8.9%
Torrent Pharmaceuticals Ltd
7.6%
Abbott India Ltd
6.6%
Apollo Hospitals Enterprise Ltd
5.9%
Lupin Ltd
5.0%
Aurobindo Pharma Ltd
4.8%
Fortis Healthcare Ltd
4.3%
Ajanta Pharma Ltd
4.3%
Ipca Laboratories Ltd
4.0%
Top industry exposure
Healthcare
97.8%
Basic Materials
0.8%
Other information
Minimum SIP
₹100
Minimum lumpsum
₹1,000
Additional lumpsum
₹1,000
Portfolio turnover
24%
Lock-in period
-
Exit load
• 1% for redemption within 30 days
Fund objective
The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes’ objectives will be achieved.
Fund manager(s)
Dhaval Shah
Dhaval Joshi

FAQs